Type 3 hypersensitivity in COVID-19 vasculitis
Copyright © 2020 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 217(2020) vom: 30. Aug., Seite 108487 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2020
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Case Reports Letter Coronavirus disease 2019 (COVID-19) Immune complex disease Interleukin-6 (IL-6) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Type III hypersensitivity Vasculitis Antibodies, Viral Antigen-Antibody Complex mehr... |
| Zusammenfassung: | Copyright © 2020 Elsevier Inc. All rights reserved. Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden, globally. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2 T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels |
|---|---|
| Beschreibung: | Date Completed 21.07.2020 Date Revised 06.06.2023 published: Print-Electronic CommentIn: Hum Cell. 2022 Dec 7;:. - PMID 36478089 Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2020.108487 |